Website
News25/Ratings9
News · 26 weeks58-75%
2025-10-262026-04-19
Mix2190d
- Other7(33%)
- Insider6(29%)
- SEC Filings5(24%)
- Leadership1(5%)
- Earnings1(5%)
- Offering1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Ribeiro Ramiro4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 362,500 shares of EyePoint common stock to fourteen new employees. The stock options were granted on April 15, 2026. The grants were approved by the Compensation Committee and made as an inducement ma
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.SCHEDULE 13G/A - EyePoint, Inc. (0001314102) (Subject)
- INSIDERSEC Form 4 filed by Duker Jay S.4 - EyePoint, Inc. (0001314102) (Issuer)
- SECEyePoint Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - EyePoint, Inc. (0001314102) (Filer)
- INSIDERPresident and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 20,000 shares of EyePoint common stock to six new employees. The stock options were granted on March 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- INSIDERChief Financial Officer Elston George gifted 5,000 shares and received a gift of 5,000 shares, decreasing direct ownership by 5% to 87,818 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SECSEC Form 10-K filed by EyePoint Inc.10-K - EyePoint, Inc. (0001314102) (Filer)
- INSIDERChief Medical Officer Ribeiro Ramiro sold $43,572 worth of shares (2,438 units at $17.87) and exercised 2,438 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SECEyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-ye
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). DURAVYU is an investigational sustained delivery therapy delivering vorolanib, a selective tyrosine ki
- PREyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w
- PREyePoint Announces Participation at Upcoming Investor ConferencesWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: TD Cowen 46th Annual Health Care ConferenceForum: Fireside Chat Date: March 3, 2026Time: 2:30 p.m. ETBarclays 28th Annual Global Healthcare Conference 2026Forum: 1x1 Investor MeetingsDate: March 10, 2026Jefferies Biotech on the Beach SummitForum: 1x1 Investor MeetingsDate: March 11, 2026RBC Capital Markets Virtual Ophthalmology ConferenceForum: Fireside ChatDate: March 25, 2
- INSIDERChief Medical Officer Ribeiro Ramiro sold $36,555 worth of shares (2,437 units at $15.00) and exercised 2,437 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Appoints Michael Campbell as Chief Commercial Officer– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 143,000 shares of EyePoint common stock to six new employees. The stock options were granted on February 13, 2026. The grants were approved by the Compensation Committee and made as an inducement mater
- PREyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 am ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutic
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint common stock to three new employees. The stock options were granted on January 15, 2026. The grants were approved by the Compensation Committee and made as an inducement mater
- INSIDERDirector Lurker Nancy converted options into 75,133 shares, increasing direct ownership by 34% to 294,346 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- INSIDERPresident and CEO Duker Jay S. converted options into 20,793 shares and covered exercise/tax liability with 10,054 shares, increasing direct ownership by 16% to 77,752 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- INSIDERChief Financial Officer Elston George converted options into 15,285 shares and covered exercise/tax liability with 4,487 shares, increasing direct ownership by 13% to 91,852 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)